At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Ixabepilone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
In Brief
A Phase 2 clinical trial evaluating Ixabepilone and Laboratory Biomarker Analysis for Recurrent Uterine Corpus Sarcoma and Uterine Corpus Leiomyosarcoma. Completed, enrolled 26 participants across 72 sites.
Detailed Summary
This phase II trial is studying the side effects and how well ixabepilone works in treating patients with recurrent or persistent leiomyosarcoma of the uterus previously treated with chemotherapy. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNRG Oncology
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionJul 2014
Study CompletionJan 2016
TodayJul 2026
First PostedOct 14, 2010
Enrollment StartNov 1, 2010
Primary CompletionJul 1, 2014
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.7 years ago
Interventions
Ixabepilonedrug
Given IV
Laboratory Biomarker Analysisother
Correlative studies